EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Rechallenge with Anti-EGFR Treatment in RAS/BRAF wt Metastatic Colorectal Cancer (mCRC) in Real Clinical Practice: Experience of the GITuD Group

Mercedes Salgado Fernández, Margarita Reboredo López, Marta Covela Rúa, Sonia Candamio, Paula González-Villarroel, Luis Felipe Sánchez-Cousido, Begoña Graña, Alberto Carral-Maseda, Soledad Cameselle-García, Vanesa Varela Pose, Maria Elena Gallardo-Martín, Nieves Martínez-Lago und 1 weitere

Targeted Oncology · 2024-07 · 19 (4) · 565-573

DOI: 10.1007/s11523-024-01062-z ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Targeted Oncology, online erschienen am 23.05.2024. Verfasst von Mercedes Salgado Fernández und 12 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Service, Complejo Hospitalario Universitario de Ourense, Ramon Puga Noguerol Street, 54, 32005, Ourense, Spain. Mercedes.Salgado.Fer…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, ErbB Receptors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Merck S.L.U..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: There are few third- and fourth-line therapeutic options for metastatic colorectal cancer (mCRC). In RAS/BRAF wild-type (wt) mCRC previously treated with anti-epidermal growth factor receptor (anti-EGFR) (first-line) and relapsed after a good response, retreatment with anti-EGFR (rechallenge) emerges as a therapeutic alternative. OBJECTIVE: The aim was to show the activity and safety of anti-EGFR rechallenge in RAS/BRAF wt mCRC in real-world practice. PATIENTS AND METHODS: A multicenter, retrospective, observational study (six hospitals of the Galician Group of Research in Digestive Tumors) was conducted. Adult patients with RAS/BRAF wt mCRC, evaluated by liquid biopsy, were included. They received anti-EGFR rechallenge (cetuximab, panitumumab) as monotherapy, or combined with chemotherapy, in third- or subsequent lines. Efficacy (overall response rate [ORR], disease control rate [DCR], overall survival [OS], and progression-free survival [PFS]) and safety (incidence of adverse events [AEs]) were assessed. RESULTS: Thirty-one patients were analyzed. Rechallenge (median 6 cycles [range 1-27], mainly cetuximab [80.7%]), started at a median anti-EGFR-free time of 18.4 months (1.7-37.5 months) after two (38.7%) or more (61.3%) lines of treatment; 64.5% of patients received a full dose. Median OS and PFS were 9.8 months (95% confidence interval [CI] 8.2-11.4) and 2.6 months (95% CI 1.7-3.4), respectively. ORR was 10%, and DCR was 30%. The most common AEs were diarrhea (35.5%), anemia (29%), emesis (6.4%), and neutropenia (6.4%); 1). Hypomagnesemia required supplements in 29% of patients. Dose delays (≥ 3 days) and reduction (≥ 20%) were reported in 11 (35.5%) and seven patients (22.6%), respectively. CONCLUSIONS: In RAS/BRAF wt mCRC patients, an anti-EGFR rechallenge provides a feasible therapeutic option with clinical benefit (survival) and a manageable safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsErbB ReceptorsHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultProto-Oncogene Proteins B-rafNeoplasm MetastasisAged, 80 and overCetuximabPanitumumab

Substanzen

ErbB ReceptorsEGFR protein, humanProto-Oncogene Proteins B-rafCetuximabBRAF protein, humanPanitumumab

Autor:innen und Institutionen

  • Medical Oncology Service, Complejo Hospitalario Universitario de Ourense, Ramon Puga Noguerol Street, 54, 32005, Ourense, Spain. Mercedes.Salgado.Fernandez@sergas.es.
  • Medical Oncology Service, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.
  • Medical Oncology Service, Hospital Universitario Lucus Augusti, Lugo, Spain.
  • Medical Oncology Service, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain.
  • Medical Oncology Service, Hospital Álvaro Cunqueiro, Vigo, Spain.
  • Medical Oncology Service, Complexo Hospitalario Universitario de Ferrol, A Coruña, Spain.

Förderung

  • Merck S.L.U.

Zitieren

APA

Salgado Fernández, M., Reboredo López, M., Covela Rúa, M., Candamio, S., González-Villarroel, P., Sánchez-Cousido, L. F., Graña, B., Carral-Maseda, A., Cameselle-García, S., Varela Pose, V., Gallardo-Martín, M. E., Martínez-Lago, N., & Galician Group of Research in Digestive Tumors (GITuD) (2024). Rechallenge with Anti-EGFR Treatment in RAS/BRAF wt Metastatic Colorectal Cancer (mCRC) in Real Clinical Practice: Experience of the GITuD Group. Targeted Oncology, 19(4), 565-573. https://doi.org/10.1007/s11523-024-01062-z

Vancouver

Salgado Fernández M, Reboredo López M, Covela Rúa M, Candamio S, González-Villarroel P, Sánchez-Cousido LF, et al. Rechallenge with Anti-EGFR Treatment in RAS/BRAF wt Metastatic Colorectal Cancer (mCRC) in Real Clinical Practice: Experience of the GITuD Group. Targeted Oncology. 2024;19(4):565-573. doi:10.1007/s11523-024-01062-z

BibTeX
@article{SalgadoFernndez2024,
  author = {Salgado Fernández, Mercedes and Reboredo López, Margarita and Covela Rúa, Marta and Candamio, Sonia and González-Villarroel, Paula and Sánchez-Cousido, Luis Felipe and Graña, Begoña and Carral-Maseda, Alberto and Cameselle-García, Soledad and Varela Pose, Vanesa and Gallardo-Martín, Maria Elena and Martínez-Lago, Nieves and Galician Group of Research in Digestive Tumors (GITuD), Galician Group of Research in Digestive Tumors (GITuD)},
  title = {Rechallenge with Anti-EGFR Treatment in RAS/BRAF wt Metastatic Colorectal Cancer (mCRC) in Real Clinical Practice: Experience of the GITuD Group},
  journal = {Targeted Oncology},
  year = {2024},
  volume = {19},
  number = {4},
  pages = {565--573},
  doi = {10.1007/s11523-024-01062-z}
}
Kostenlos starten →